Patent classifications
A61P31/10
ANTIFUNGAL COMPOSITION CONTAINING CARBAZOLE COMPOUND AS ACTIVE INGREDIENT
The present invention relates to an antifungal composition containing a carbazole compound as an active ingredient. The carbazole compound according to the present invention inhibits the growth of not only Candida but also fungi such as yeast, and neutralizes the pathogenicity of Candida by inhibiting morphological transformation thereof. Thus, the carbazole compound is very useful as an antifungal composition capable of treating Candida infection.
NOVEL THERAPEUTIC AGENT FOR PROTOTHECA DISEASE
The present invention has an object of providing a composition that is effective for the treatment of a prototheca disease. According to the present invention, a composition containing ravuconazole as an active ingredient, which is administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii, is provided.
NOVEL THERAPEUTIC AGENT FOR PROTOTHECA DISEASE
The present invention has an object of providing a composition that is effective for the treatment of a prototheca disease. According to the present invention, a composition containing ravuconazole as an active ingredient, which is administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii, is provided.
1,2,4-oxadiazole derivatives as immunomodulators
The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) ##STR00001## In the formula Q is O, R.sub.1 is the side chain of Ser, R.sub.2 is —CO-Thr, R.sub.3 is the side chain of Asn or Glu, and R.sub.4, R.sub.5 and R.sub.6 are each H.
System and method for manufacturing custom nails
A system and method for manufacturing custom fit artificial nails includes a 3D surface scanning module and a 3D printing module and use thereof. A central processing module is connected to the 3D surface scanning module and the 3D printing module and performs: operating the 3D surface scanning module to obtain an image of a user's hands/feet; processing the image to create an input 3D model of nails of the user; generating an output 3D model corresponding to artificial nails matching dimensions of the user's nails according to the 3D input model; operating the 3D printing module to manufacture artificial nails according to the output 3D model; and generating medical data by correlating the identified features of the user's nails with known medical conditions, in order to diagnose a medical condition of the user which is known to exhibit the identified features as a symptom. Alternatively, or additionally, medicinal ingredient may be included in the artificial nail to treat the medical condition of the user. Embedded devices, sensors or an RFID chip may be integrated into the artificial nail.
Heterocycle substituted pyridine derivative antifungal agents
Described herein are heterocycle substituted pyridine derivative antifungal agents and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.
Heterocycle substituted pyridine derivative antifungal agents
Described herein are heterocycle substituted pyridine derivative antifungal agents and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.
Antimicrobial peptide Scyreprocin of <i>Scylla paramamosain </i>and method thereof
The present disclosure discloses an antimicrobial peptide Scyreprocin of Scylla paramamosain and a method thereof, wherein an amino acid sequence of the antimicrobial peptide Scyreprocin comprises a sequence shown in SEQ ID NO 01, and the antimicrobial peptide is expressed and purified by using genetic engineering technology. The recombinant antimicrobial peptide Scyreprocin has advantages of wide antimicrobial spectrum, good antimicrobial effect, and rapid germicidal rate, shows great application significance, and has good application in preparation of antimicrobial agents. The recombinant antimicrobial peptide Scyreprocin has no cytotoxicity to mouse hepatocytes AML12, human liver cells L02, and can be safely used for medical treatment or can be used as a feed composition.
Antimicrobial peptide Scyreprocin of <i>Scylla paramamosain </i>and method thereof
The present disclosure discloses an antimicrobial peptide Scyreprocin of Scylla paramamosain and a method thereof, wherein an amino acid sequence of the antimicrobial peptide Scyreprocin comprises a sequence shown in SEQ ID NO 01, and the antimicrobial peptide is expressed and purified by using genetic engineering technology. The recombinant antimicrobial peptide Scyreprocin has advantages of wide antimicrobial spectrum, good antimicrobial effect, and rapid germicidal rate, shows great application significance, and has good application in preparation of antimicrobial agents. The recombinant antimicrobial peptide Scyreprocin has no cytotoxicity to mouse hepatocytes AML12, human liver cells L02, and can be safely used for medical treatment or can be used as a feed composition.
COMBINATION TREATMENT OF SYSTEMIC FUNGAL INFECTIONS
Disclosed are compositions comprising a polyene macrolide antibiotic and an azole antifungal, and packaged pharmaceutical products comprising the disclosed compositions. Also disclosed are methods of treating systemic fungal infections comprising co-administering to a mammal a polyene macrolide antibiotic and an azole antifungal (conjoint administration). The co-administration may be simultaneous (e.g., in a single formulation or in separate formulations), sequential, or staggered.